Clinical Trials at Sarah Cannon Research Institute
As of September 2026, 59 paid clinical trials are recruiting at Sarah Cannon Research Institute, located at Sarah Cannon Research Institute, 250 25th Ave N, Nashville, TN 37203, phone (615) 329-7274 in Nashville, Tennessee. Active studies at this site cover conditions such as Breast Cancer, Colorectal Cancer and Advanced Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Nashville
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
61 clinical trials at Sarah Cannon Research Institute
·Clear filters·Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
FOG-001 in Locally Advanced or Metastatic Solid Tumors
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
CAR-T Long Term Follow Up (LTFU) Study
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A Study of LY4175408 in Participants With Advanced Cancer
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Study of SGR-3515 In Participants With Advanced Solid Tumors.
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
TLN-372 in Advanced KRAS Mutant Solid Tumors
Common conditions studied in Nashville
- Breast Cancer (43 active studies)
- Colorectal Cancer (32 active studies)
- Advanced Solid Tumor (30 active studies)
- Ovarian Cancer (28 active studies)
- Prostate Cancer (24 active studies)
- Multiple Myeloma (23 active studies)
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,351 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (43), Colorectal Cancer (32), Advanced Solid Tumor (30), Ovarian Cancer (28), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (559), Cardiovascular (89), Neurology & pain (61). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Sarah Cannon Research Institute?
Sarah Cannon Research Institute is located at Sarah Cannon Research Institute, 250 25th Ave N, Nashville, TN 37203. Use the Google Maps link in the intro above to get directions.
How do I contact Sarah Cannon Research Institute?
You can reach Sarah Cannon Research Institute by phone at (615) 329-7274. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.